Patient Enrollment

touchpoints℠ Support Services | Vivitrol® (naltrexone for extended-release injectable suspension)

COMPLETE ALL FIELDS TO AVOID PROCESSING DELAYS. PRESCRIPTION ONLY VALID IF FAXED. FAX COMPLETED FORM TO: 1-877-329-8484

QUESTIONS? CALL 1-800-VIVITROL (1-800-848-4876), 9AM–8PM (EST).

TP ID# (Touchpoints Use Only): _____

Admittance Date: _____ Discharge Date: _____

1. PRESCRIBER OR FACILITY INFORMATION

Prescriber Name* Andreas J. Edrich MD

State License # Co37249 DEA # BE6063541

Prescriber Phone # 303-792-3333 NPI # 1982665568

Facility Name Heritage Hills Family Me Fax # 303-792-3361

Address 7000 E Belleview Ave, 100

City Greenwood Village State co Zip Code 80111

Staff Contact Name Leah Camara

Staff Contact Phone # 303-792-3333

Staff Contact E-mail none

2. PATIENT INFORMATION

Name (First) (Last)

Date of Birth Gender ☐ Male ☐ Female

Address

City State Zip Code

Home Phone # Mobile Phone #

Best Day to Call ☐ M ☐ T ☐ W ☐ TH ☐ F

Best Time to Call ☐ Morning ☐ Afternoon ☐ Evening

E-mail Address

→ *INSTRUCT PATIENT TO LIST ALTERNATE CONTACTS ON PAGE 2.*

3. PATIENT DIAGNOSIS—Please complete the diagnosis code(s) you would like to use by filling in the additional digits.

(A list of codes can be found on page 3, section 12)

Alcohol Dependence ICD-10	Opioid Dependence ICD-10
F10. _____	F11. _____
F10. _____	F11. _____
F10. _____	F11. _____
F10. _____	F11. _____
F10. _____	F11. _____
Other _____	Other _____

☐ Check if patient has concurrent medications

Patient has tried and failed the following medication(s):

Please list any known allergies to medications or other substances:

Patient's concurrent medications:

4. INJECTION PROVIDER/SPECIALTY PHARMACY INFORMATION

Will your patient receive ongoing injections at your location?

☑ Yes, patient will receive all injections at this location. Complete step B of this section.

☐ No, patient will transition to a new provider after the first dose. Complete steps A and B of this section.

A. Injecting provider

☐ A new provider is unknown; need assistance from Touchpoints to locate one

☐ Touchpoints should contact provider below to coordinate ongoing care for this patient

Provider Name Phone #

Provider Address

B. Shipping details

Patient needs VIVITROL delivered by (date) _____ /_____ /_____

Preferred pharmacy (if applicable)

Special shipping instructions/restrictions

5. PATIENT INSURANCE INFORMATION

A. Payment Method ☐ Insured ☐ Paying out-of-pocket

B. **ATTACH A COPY OF BOTH SIDES OF THE PATIENT'S INSURANCE CARD(S).**

C. IF YOU ELECT NOT TO ATTACH AN INSURANCE CARD, COMPLETE SECTION BELOW.

PRIMARY INSURANCE / MEDICAL INSURANCE

Insurance Type ☐ HMO ☐ PPO ☐ Medicaid ☐ Medicare ☐ QHP

Carrier Name

Policyholder Name PA # (if obtained)

Relationship to Patient Carrier Phone #

Policyholder Employer Name

Policy # Group ID #

PHARMACY BENEFIT PLAN (PBM)

PBM Name

Policyholder Name

Relationship to Patient PBM Phone #

Policyholder Employer Name

Policy # Rx Grp

Rx BIN # Rx PCN

Co-pay Card Number (if already obtained)

6. PRESCRIPTION INFORMATION AND ATTESTATION

*PRESCRIBER SIGNATURE MUST BE THE SAME AS THE PRESCRIBER NAME ABOVE

Patient Name Andreas J. Edrich MD

VIVITROL 380 mg x 1 unit Inject 380 mg IM every 4 weeks or every 1 month

Provider State License # CO37249

Refill 11 times (Complete refills to minimize interruption in monthly VIVITROL therapy)

By signing below, I verify that the information provided in this Touchpoints enrollment form is complete and accurate to the best of my knowledge. I understand that Alkermes, Inc., reserves the right at any time and for any reason, without notice, to modify this Touchpoints enrollment form or to modify or discontinue any services or assistance provided through Touchpoints. Finally, I authorize Alkermes, its affiliates, representatives and agents as my designated agents to use and disclose my patient's health information as necessary to verify the accuracy of any information provided, to provide reimbursement services through Touchpoints, to forward the above prescription, by fax or other mode of delivery, to a pharmacy for fulfillment, and (as applicable) to assess my patient's eligibility for co-pay assistance.

Prescriber's Signature X _____

(If applicable) Prescriber's Signature (no stamps allowed)

X _____ Dispense as Written

X _____ Substitution Permitted

Date of Signature _____

PLEASE SEE IMPORTANT SAFETY INFORMATION ON PAGE 4. PLEASE SEE PRESCRIBING INFORMATION AND MEDICATION GUIDE, OR VISIT VIVITROL.COM. PLEASE REVIEW MEDICATION GUIDE WITH PATIENTS.

Patient Enrollment

touchpoints℠ Support Services | Vivitrol® (naltrexone for extended-release injectable suspension)

PATIENTS SHOULD COMPLETE ALL FIELDS ON THIS PAGE. **QUESTIONS? CALL 1-800-VIVITROL (1-800-848-4876), 9AM–8PM (EST).**

7. ALTERNATE PATIENT CONTACT(S)

By signing below, I authorize my Contact(s), listed below, to receive logistical and administrative information related to my treatment, such as appointment reminders, and to make decisions on my behalf—for which I will remain liable—regarding delivery of VIVITROL® (naltrexone for extended-release injectable suspension). Alkermes is not liable for any decision(s) made by the Contact(s) or actions taken in reliance on such Contact(s) decisions.

Please list any Contacts authorized as set forth above:

Contact Name (1)	**Relationship**	**Phone #**
Contact Name (2)	**Relationship**	**Phone #**
Patient's Signature X	**Date of Signature**	**Phone #**

8. PATIENT AUTHORIZATION FOR USE/DISCLOSURE OF HEALTH INFORMATION

By signing below, **I** _____ **authorize: 1.** my prescribing healthcare provider, **2.** the healthcare provider who will administer VIVITROL to me, **3.** the pharmacy(ies) to which my VIVITROL prescription is sent for fulfillment (the "Pharmacy"), and **4.** my health plans and insurers (collectively, my "Healthcare Entities") to use and disclose to: **1.** Alkermes, Inc. and the companies working with Alkermes, Inc. to provide the VIVITROL patient support services I request, which are United BioSource Corporation, OPUS Health, LASH Group, Human Care Systems (collectively, "Alkermes") and **2.** my Contact(s) listed above (together with Alkermes, the "Recipients") health information related to my medical condition, including information about my drug or alcohol addiction, my mental health condition(s), my treatment with VIVITROL, my insurance coverage, as well as the information requested in this form (taken together, "Information") **for the specific purposes** of allowing Alkermes to facilitate: **1.** ordering, delivering and administering VIVITROL, **2.** conducting reimbursement verification and obtaining payment from my health plan(s) and insurer(s), **3.** providing me with educational and therapy support services by mail, text-messaging, e-mail, and/or telephone, which may include sending me product information materials and treatment reminders, **4.** referring me to, or determining my eligibility for, other programs, foundations or alternative sources of funding or coverage to help me with the costs of VIVITROL and **5.** reviewing and analyzing fulfillment of VIVITROL prescriptions. **Information May Be Further Disclosed:** I understand that Information disclosed pursuant to this authorization could be re-disclosed by a Recipient and may no longer be protected by federal privacy law (HIPAA).

I understand that signing this authorization is voluntary and if I do not sign this authorization it will not affect my ability to obtain treatment, insurance or insurance benefits from my Healthcare Entities. I understand, however, that if I do not sign this authorization, I will not be eligible to receive the educational, patient support or other services described above, which are being provided by, or on behalf of, Alkermes. I will consult with my healthcare provider before making any treatment decisions. I understand I have the right to receive a copy of this authorization after I sign. I understand that the Pharmacy may receive payment from Alkermes, Inc. in exchange for Information.

I may withdraw this authorization at any time by mailing or faxing a written request to Touchpoints Reimbursement Support, 1670 Century Center Parkway, Memphis, TN 38134. Withdrawal of this authorization will end my consent to further disclosures of Information authorized herein by my Healthcare Entities when they receive notice of my withdrawal, but will not affect previous disclosures and uses pursuant to this authorization or as permitted by applicable law. This authorization expires on the earlier of **(1)** five years from the date of signature below or **(2)** the maximum period permitted by applicable state law, unless I withdraw it earlier as set forth above.

Patient's Signature X	**Date of Signature**
Parent/Guardian/Legal Representative's Signature‡ X **Authority/Relationship to Patient**	

‡If patient is a minor without capacity to act alone under state law, signature of patient and parent/guardian/legal representative is required.

9. CO-PAY INFORMATION FOR ELIGIBLE PATIENTS§

☐ ***(Check if "yes")*** **I would like to receive co-payment assistance from Alkermes.**

☐ I certify that I am at least 18 years old, and I am being treated for opioid dependence after detox or alcohol dependence.

Please confirm that you understand the eligibility requirements for the VIVITROL® Co-pay Savings Program:

Co-payment assistance for VIVITROL is not valid for prescriptions that are purchased (in full or in part) by any federal, state or government funded program. Such programs include, but are not limited to:

- Medicare, including Medicare Part D and Medicare Advantage plans
- Medicaid, including Medicaid Managed Care and Alternative Benefit Plans ("ABPs") under the Affordable Care Act
- Medigap
- Veterans Administration ("VA")
- Department of Defense ("DoD")
- TRICARE®
- State-funded programs such as medical or pharmaceutical assistance programs

I agree that I understand the eligibility requirements described above. I certify that I am not using, and I will not use, any federal or state funded program to help pay for my VIVITROL prescription. I understand that if I do use any benefits from state, federal or other government funded program to help pay for my VIVITROL prescription, I will no longer be eligible for co-pay support for VIVITROL. I agree to comply with any requirements of my insurer(s) regarding co-pay support, including disclosure of the amount of co-pay support I receive to my insurer(s).

By signing below I agree that I understand, and will comply with, the terms of this VIVITROL® Co-pay Savings Program.

☐ **YES** ☐ **NO** **Patient's Signature X** _____ **Date of Signature** _____

§**Eligibility for Sponsored Co-pay Assistance:** Please see page 3, section 11.

Patient Enrollment

10. INJECTION PROVIDER/SPECIALTY PHARMACY SELECTION INFORMATION (AS APPLICABLE)

If you have requested injection services for your patient, Touchpoints will identify several injectors based on geographic proximity to your patient's address listed on the enrollment form (from closest to farthest from such address).

These injection providers are listed on the VIVITROL Provider Locator[II] at VIVITROL.com.

These options will be provided to you for your patient. We will also contact the selected injection services provider to help coordinate injection services.

Upon request, prescriptions of patients enrolled in Touchpoints are routed to qualified pharmacies based on insurance plan requirements, provider selection, patient preference and information obtained by Alkermes on pharmacy capability and performance in dispensing VIVITROL prescriptions. Participation is open to all qualified pharmacies free of charge. Interested pharmacies may contact 1-800-VIVITROL (1-800-848-4876).

11. ELIGIBILITY FOR SPONSORED CO-PAY ASSISTANCE

Offer valid only for prescriptions for FDA-approved indications. Patients must be at least 18 years old. If patients are purchasing their VIVITROL prescriptions with benefits from Medicare, including Medicare Part D or Medicare Advantage plans; Medicaid, including Medicaid Managed Care or Alternative Benefit Plans ("ABPs") under the Affordable Care Act; Medigap; Veterans Administration ("VA"); Department of Defense ("DoD"); TRICARE®; or any similar state funded programs such as medical or pharmaceutical assistance programs, they are not eligible for this offer. Void where prohibited by law, taxed or restricted. Alkermes, Inc. reserves the right to rescind, revoke or amend these offers without notice.

12. PATIENT DIAGNOSIS CODES

Alcohol Dependence:

(ICD-10)	
F10.2	Alcohol dependence
- F10.20	Uncomplicated
- F10.21	In remission
- F10.22	Alcohol dependence with intoxication
- F10.220	Uncomplicated
- F10.221	Delirium
- F10.229	Unspecified
F10.23	Alcohol dependence with withdrawal
- F10.230	Uncomplicated
- F10.231	Delirium
- F10.232	With perceptual disturbance
- F10.239	Unspecified
F10.24	With alcohol-induced mood disorder
F10.25	Alcohol dependence with alcohol-induced psychotic disorder
- F10.250	With delusions
- F10.251	With hallucinations
- F10.259	Unspecified
F10.26	With alcohol-induced persisting amnestic disorder
F10.27	With alcohol-induced persisting dementia
F10.28	Alcohol dependence with other alcohol-induced disorders
- F10.280	Alcohol dependence with alcohol-induced anxiety disorder
- F10.281	Alcohol dependence with alcohol-induced sexual dysfunction
- F10.282	Alcohol dependence with alcohol-induced sleep disorder
- F10.288	Alcohol dependence with other alcohol-induced disorder
F10.29	With unspecified alcohol-induced disorder

Opioid Dependence:

(ICD-10)	
F11.2	Opioid dependence
- F11.20	Uncomplicated
F11.21	In remission
F11.22	Opioid dependence with intoxication
- F11.220	Uncomplicated
- F11.221	Delirium
- F11.222	With perceptual disturbance
- F11.229	Unspecified
F11.23	With withdrawal
F11.24	With opioid-induced mood disorder
F11.25	Opioid dependence with opioid-induced psychotic disorder
- F11.250	With delusions
- F11.251	With hallucinations
- F11.259	Unspecified
F11.28	Opioid dependence with other opioid-induced disorder
- F11.281	Opioid dependence with other opioid-induced sexual dysfunction
- F11.282	Opioid dependence with other opioid-induced sleep disorder
- F11.288	Opioid dependence with other opioid-induced disorder
F11.29	With unspecified opioid-induced disorder

[II] Inclusion in the Locator is voluntary and free of charge to qualified healthcare providers and, along with the provider-specific information in the Provider Locator, is based on healthcare provider responses. Inclusion in the Locator does not imply a referral, recommendation, or endorsement by Alkermes. Alkermes has not independently verified the qualifications of any healthcare provider included in the Locator. We recommend that you research the credentials, qualifications, and experience of each provider before confirming an appointment. Alkermes shall not be liable to you or to anyone for any decision made or action taken in reliance on this information.

Patient Enrollment

IMPORTANT SAFETY INFORMATION FOR VIVITROL® (naltrexone for extended-release injectable suspension)

INDICATIONS

VIVITROL is indicated for:

- Treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting. Patients should not be actively drinking at the time of initial VIVITROL administration.
- Prevention of relapse to opioid dependence, following opioid detoxification.
- VIVITROL should be part of a comprehensive management program that includes psychosocial support.

CONTRAINDICATIONS

VIVITROL is contraindicated in patients:

- Receiving opioid analgesics
- With current physiologic opioid dependence
- In acute opioid withdrawal
- Who have failed the naloxone challenge test or have a positive urine screen for opioids
- Who have exhibited hypersensitivity to naltrexone, polylactide-co-glycolide (PLG), carboxymethylcellulose, or any other components of the diluent

WARNINGS AND PRECAUTIONS

Vulnerability to Opioid Overdose: Because VIVITROL blocks the effects of exogenous opioids for approximately 28 days after administration, patients are likely to have a reduced tolerance to opioids after opioid detoxification. As the blockade dissipates, use of previously tolerated doses of opioids could result in potentially life-threatening opioid intoxication (respiratory compromise or arrest, circulatory collapse, etc). Cases of opioid overdose with fatal outcomes have been reported in patients who used opioids at the end of a dosing interval, after missing a scheduled dose, or after discontinuing treatment. Patients and caregivers should be told of this increased sensitivity to opioids and the risk of overdose.

Any attempt by a patient to overcome the VIVITROL blockade by taking opioids may lead to fatal overdose. Patients should be told of the serious consequences of trying to overcome the opioid blockade.

Injection Site Reactions: VIVITROL injections may be followed by pain, tenderness, induration, swelling, erythema, bruising, or pruritus; however, in some cases injection site reactions may be very severe. Injection site reactions not improving may require prompt medical attention, including, in some cases, surgical intervention. Inadvertent subcutaneous/adipose layer injection of VIVITROL may increase the likelihood of severe injection site reactions. Select proper needle size for patient body habitus, and use only the needles provided in the carton. Patients should be informed that any concerning injection site reactions should be brought to the attention of their healthcare provider.

Precipitation of Opioid Withdrawal: Withdrawal precipitated by administration of VIVITROL may be severe. Some cases of withdrawal symptoms have been severe enough to require hospitalization and management in the ICU. To prevent precipitated withdrawal, patients, including those being treated for alcohol dependence:

- Should be opioid-free (including tramadol) for a minimum of 7–10 days before starting VIVITROL.
- Patients transitioning from buprenorphine or methadone may be vulnerable to precipitated withdrawal for as long as two weeks.

Patients should be made aware of the risk associated with precipitated withdrawal and be encouraged to give an accurate account of last opioid use.

Hepatotoxicity: Cases of hepatitis and clinically significant liver dysfunction have been observed in association with VIVITROL. Warn patients of the risk of hepatic injury; advise them to seek help if experiencing symptoms of acute hepatitis. Discontinue use of VIVITROL in patients who exhibit acute hepatitis symptoms.

Depression and Suicidality: Alcohol- and opioid-dependent patients taking VIVITROL should be monitored for depression or suicidal thoughts. Alert families and caregivers to monitor and report the emergence of symptoms of depression or suicidality.

When Reversal of VIVITROL Blockade Is Required for Pain Management: For VIVITROL patients in emergency situations, suggestions for pain management include regional analgesia or use of non-opioid analgesics. If opioid therapy is required to reverse the VIVITROL blockade, patients should be closely monitored by trained personnel in a setting staffed and equipped for CPR.

Eosinophilic Pneumonia: Cases of eosinophilic pneumonia requiring hospitalization have been reported. Warn patients of the risk of eosinophilic pneumonia and to seek medical attention if they develop symptoms of pneumonia.

Hypersensitivity Reactions: Patients should be warned of the risk of hypersensitivity reactions, including anaphylaxis.

Intramuscular Injections: As with any IM injection, VIVITROL should be administered with caution to patients with thrombocytopenia or any coagulation disorder.

Alcohol Withdrawal: Use of VIVITROL does not eliminate nor diminish alcohol withdrawal symptoms.

ADVERSE REACTIONS

Serious adverse reactions that may be associated with VIVITROL therapy in clinical use include severe injection site reactions, eosinophilic pneumonia, serious allergic reactions, unintended precipitation of opioid withdrawal, accidental opioid overdose, and depression and suicidality. The adverse events seen most frequently in association with VIVITROL therapy for alcohol dependence include nausea, vomiting, injection site reactions (including induration, pruritus, nodules, and swelling), muscle cramps, dizziness or syncope, somnolence or sedation, anorexia, decreased appetite or other appetite disorders. The adverse events seen most frequently in association with VIVITROL in opioid-dependent patients also include hepatic enzyme abnormalities, injection site pain, nasopharyngitis, insomnia, and toothache.

You are encouraged to report side effects to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

PLEASE SEE PRESCRIBING INFORMATION AND MEDICATION GUIDE, OR VISIT VIVITROL.COM.
PLEASE REVIEW MEDICATION GUIDE WITH PATIENTS.